CaRES (Contrast Echocardiography Registry for Safety Surveillance): A prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice

Journal of the American Society of Echocardiography

Volumn 25, Issue 7, 2012, Pages 790-795

  Weiss, Robert J ^a   Ahmad, Masood ^c   Villanueva, Flordeliza ^b   Schmitz, Stephen ^e   Bhat, Gajanan ^e   Hibberd, Mark G ^e   Main, Michael L ^d  

^a Maine Research Associates   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^e Clinical Research   (United States)

Author keywords

Contrast echocardiography; Safety; Ultrasound contrast agents

Indexed keywords

ECHO CONTRAST MEDIUM; OXYGEN; PERFLUTREN;

ACUTE HEART INFARCTION; ADULT; AGED; ANAPHYLAXIS; ARTICLE; BACKACHE; CARDIOPULMONARY ARREST; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ARRHYTHMIA; HUMAN; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OXYGEN SATURATION; PATIENT MONITORING; PATIENT SAFETY; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; PULSE OXIMETRY; REST ECHOCARDIOGRAPHY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; STRESS ECHOCARDIOGRAPHY; TELECONSULTATION; TREMOR; ULTRASOUND; UNITED STATES; VITAL SIGN;

CARDIOVASCULAR DISEASES; CONTRAST MEDIA; DRUG TOXICITY; ECHOCARDIOGRAPHY; FEMALE; FLUOROCARBONS; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84863000156     PISSN: 08947317     EISSN: 10976795     Source Type: Journal    
DOI: 10.1016/j.echo.2012.04.002     Document Type: Article

References (22)

1. Mulvagh SL, Rakowski H, Vannan MA, Abdelmoneim SS, Becher H, Bierig SM, et al. American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr 2009;21:1179-201.
2. Shaw LJ. Impact of contrast echocardiography on diagnostic algorithms: pharmacoeconomic implications. Clin Cardiol 1997;20:I39-48. (Pubitemid 27476217)
3. Senior R, Dwivedi G, Hayat SA, Lim TK. Clinical benefits of contrast-enhanced echocardiography during rest and stress examinations. Eur J Echocardiogr 2005;6:S6-13.
4. Kitzman DW, Goldman ME, Gillam LD, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000;86:669-74.
5. US Food and Drug Administration. DEFINITY®: vial for (perflutren lipid microsphere) injectable suspension. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2007/021064s007lbl.pdf. Accessed January 5, 2011.
6. Kusnetzky LL, Khalid A, Khumri TM, Moe TG, Jones PG, Main ML. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 patients. J Am Cardiol Coll 2008;51:1704-6.
7. Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA 2008;299:2023-5. (Pubitemid 351656599)
8. Wei K, Mulvagh SL, Carson L, Davidoff R, Grimm RA, Wilson S, et al. The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr 2008;11:1202-6.
9. Gabriel RS, Smyth YM, Menon V, Klein AL, Grimm RA, Thomas JD, et al. Safety of ultrasound contrast agents in stress echocardiography. Am J Cardiol 2008;102:1269-72.
10. Shaikh K, Chang SM, Peterson L, Rosendahl-Garcia K, Quinones MA, Nagueh SF, et al. Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress. Am J Cardiol 2008;102:1444-59.
11. Main ML, Ryan AC, Davis TE, Albano MP, Kusnetzky LL, Hibberd M. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients). Am J Cardiol 2008;102:1742-6.
12. Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G, Toli C, et al. Safety of myocardial flash-contrast echocardiography in combination with dobutamine stress testing for the detection of ischemia in 5250 studies. Heart 2008;94:1571-7.
13. Dolan MS, Gala SS, Dodla S, Abdelmoneim SS, Xie F, Cloutier D, et al. Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography: a multicenter experience. J Am Coll Cardiol 2009;53:32-8.
14. Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, et al. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients. J Am Coll Cardiol Img 2009;2:1048-56.
15. Main ML, Goldman JH, Grayburn PA. Ultrasound contrast agents: balancing safety versus efficacy. Expert Opin Drug Saf 2009;8:49-56.
16. Main ML. Ultrasound contrast agent safety: from anecdote to evidence. J Am Coll Cardiol Img 2009;2:1057-9.
17. US Food and Drug Administration. FDA advisory committee briefing document: Cardiovascular and Renal Drugs Advisory Committee: June 24, 2008: safety considerations in the development of ultrasound contrast agents. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4369b1-01. pdf. Accessed January 6, 2012.
18. US Food and Drug Administration. DEFINITY® (perflutren lipid microsphere) injectable suspension. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/021064s011lbl.pdf. Accessed January 6, 2012.
19. Beller GA. Importance of consideration of radiation doses from cardiac imaging procedures and risks of cancer. J Nucl Cardiol 2010;17:1-3.
20. Center for Devices and Radiological Health, US Food and Drug Administration. Initiative to reduce unnecessary radiation exposure from medical imaging. Available at: http://www.fda.gov/downloads/RadiationEmittingProducts/ RadiationSafety/RadiationDoseReduction/UCM200087.pdf. Accessed April 19, 2012.
21. Einstein AJ, Moser KW, Thompson RC, Cerqueira MD, Henzlova MJ. Radiation dose to patients from cardiac diagnostic imaging. Circulation 2007;116:1290-305. (Pubitemid 47517541)
22. Fazel R, Krumholz HM, Wang Y, Ross JS, Chen J, Ting HH, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009;361:849-57.